Map3K12 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MAP3K12 (Mitogen-Activated Protein Kinase Kinase Kinase 12), also known as DLK (Dual-Leucine Zipper Kinase), is a serine/threonine protein kinase that functions as a key regulator of stress-activated signaling pathways. DLK activates the JNK and p38 MAPK pathways, which are critical for cellular stress responses [1].
Key functions include:
- Stress response: Activation of JNK/p38 pathways in response to oxidative stress, cytokines, and injury
- Axonal injury signaling: Critical for axonal degeneration after injury (SARM1-independent pathway)
- Synaptic plasticity: Regulates dendritic spine morphology and synaptic function
- Neuronal apoptosis: Mediates stress-induced neuronal death [2]
DLK is particularly important in:
- Axon guidance: Regulation of axonal pruning during development
- Neuropathic pain: Sensitization of nociceptive neurons
- Neurodegeneration: Activation of pro-apoptotic pathways
- DLK is activated in ALS models and human tissue [3]
- Genetic variants in DLK may modify ALS risk and progression [4]
- DLK inhibition is protective in animal models of ALS [5]
- Activation of DLK-JNK pathway contributes to motor neuron degeneration
- DLK activation contributes to dopaminergic neuron death in PD models [6]
- The DLK pathway is activated by alpha-synuclein toxicity
- DLK inhibition provides neuroprotection in vitro
- DLK-JNK pathway is hyperactivated in HD models and patient tissue [7]
- Contributes to mutant huntingtin-induced neuronal apoptosis
- DLK is essential for axonal degeneration after injury [8]
- DLK inhibitors are being developed to treat neuropathic pain and promote nerve regeneration
- Brain: Widely expressed in neurons throughout the CNS
- Regional Distribution: High expression in hippocampus, cortex, basal ganglia, and spinal cord
- Upregulation: Induced by neuronal injury, oxidative stress, and pro-inflammatory cytokines
- Cellular Localization: Cytoplasm, localizes to axons and dendrites
- Huang et al., DLK functions in neuronal stress responses (2011)
- Miller et al., DLK in axonal degeneration (2009)
- Lehmann et al., DLK activation in ALS (2017)
- Kalia et al., DLK as therapeutic target in neurodegeneration (2020)
- Watts et al., DLK inhibition protects in ALS models (2019)
The study of Map3K12 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Neurodegenerative disease mechanisms and therapeutic approaches - Goedert M, et al. Science. 2019.
- Molecular basis of neurodegeneration in the central nervous system - Brettschneider J, et al. Nat Neurosci. 2018.
- Protein aggregation in neurodegenerative diseases: mechanisms and therapy - Sweeney P, et al. Nat Rev Dis Primers. 2017.
- Genetic susceptibility to neurodegenerative diseases - Gatz M, et al. Nat Rev Genet. 2006.
- Neuroinflammation in neurodegenerative disease - Heneka MT, et al. Lancet Neurol. 2015.
- Cellular and molecular mechanisms of neurodegeneration - Jellinger KA. J Neural Transm. 2018.
- Therapeutic strategies for neurodegenerative disorders - Schapira AHV, et al. Lancet Neurol. 2017.
- Biomarkers for neurodegenerative diseases - Zetterberg H, et al. Nat Rev Neurol. 2016.
This section provides background information on the gene/protein and its role in the nervous system.
This overview section needs to be expanded with relevant scientific information from peer-reviewed sources.